{"id":813287,"date":"2022-08-10T19:30:32","date_gmt":"2022-08-10T17:30:32","guid":{"rendered":"https:\/\/15.161.165.86\/non-categorizzato\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/"},"modified":"2022-08-10T19:30:32","modified_gmt":"2022-08-10T17:30:32","slug":"prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/","title":{"rendered":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development"},"content":{"rendered":"Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEO\n\nSAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. Dr. Nohaile joins from Generate Biomedicines and succeeds Prellis Bio founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat. The new investment brings Prellis Bio\u2019s funding to date to $64.5 million. The capital will be used to expand Prellis Bio\u2019s
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEO SAN FRANCISCO–(BUSINESS WIRE)–Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-813287","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nPrellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEO SAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-10T17:30:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development\",\"datePublished\":\"2022-08-10T17:30:32+00:00\",\"dateModified\":\"2022-08-10T17:30:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\"},\"wordCount\":826,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\",\"name\":\"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-08-10T17:30:32+00:00\",\"dateModified\":\"2022-08-10T17:30:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/","og_locale":"en_US","og_type":"article","og_title":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez","og_description":"Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEO SAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/","og_site_name":"BeBeez","article_published_time":"2022-08-10T17:30:32+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/"},"author":{"name":"","@id":""},"headline":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development","datePublished":"2022-08-10T17:30:32+00:00","dateModified":"2022-08-10T17:30:32+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/"},"wordCount":826,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/","name":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-08-10T17:30:32+00:00","dateModified":"2022-08-10T17:30:32+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/prellis-biologics-appoints-new-ceo-raises-35-million-in-series-c-funding-to-leverage-human-immune-system-biology-to-de-risk-and-accelerate-therapeutics-drug-discovery-and-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/813287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=813287"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/813287\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=813287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=813287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=813287"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=813287"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=813287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}